Almac and TTP Labtech form fluorescence lifetime technology alliance

Published: 7-Jan-2013 Featured companies: Almac Group
Research & Development

With the aim of improving screening performance


Almac and TTP Labtech, a lab instrumentation company based near Cambridge in the UK, have formed a fluorescence lifetime (FLT) technology alliance to improve screening performance.

FLT offers a robust, antibody free, homogeneous assay platform that enables the user to avoid interference from fluorescent compounds within a screening library. Developed using experience in peptide engineering and chemical synthesis and design, Almac says its Flexyte assays harness the power and potential of FLT to provide an efficient and economical platform for screening and profiling. The evolving assay platform offers solutions for many major therapeutic target classes including kinases, proteases, phosphatases, DUB and an increasing number of epigenetic targets.

TTP Labtech’s Ameon system is the next generation of FLT reader technology. By offering real-time decay curve analysis, the system is said to provide a combination of speed, precision, and data quality for FLT assays that can be integrated into HTS workflows.

Featured companies

The Almac Group is an established contract development and manufacturing organisation which provides an extensive range of integrated services to the pharmaceutical and biotech...
See more

You may also like

Manufacturing

Formosa Pharmaceuticals licenses Almac Discovery's bispecific ADC, ALM-401

Read more
The novel, first-in-class engineered bispecific antibody-drug conjugate (ADC) will be progressed through the next phases of CMC and drug development by Formosa

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients
  5. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study

Relevant companies

See more

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Formosa Pharmaceuticals licenses Almac Discovery's bispecific ADC, ALM-401

The novel, first-in-class engineered bispecific antibody-drug conjugate (ADC) will be progressed through the next phases of CMC and drug development by Formosa
Regulatory

Almac launches PNPLA3 kit to support liver disease research

New tool enables deeper genetic insight into MASLD and MASH progression
Research & Development

Almac invests in analytical capabilities with new spectroscopy instrumentation at Craigavon lab

The £500k investment will bring Agilent's 6545XT AdvanceBio Q-TOF Mass Spectrometer and Malvern's Panalytical Empyrean X-Ray Powder Diffractometer to the lab
Research & Development

Almac Group announces £11m investment to expand global analytical services

The Almac Group has announced an £11m investment and the creation of more than 100 new jobs to expand its global analytical services capabilities
Manufacturing

Almac’s Charnwood facility receives FDA approval for oral dose development and manufacturing

The facility, which focuses on the manufacture of high potency oral dosage forms, has been approved for use by the FDA
Research & Development

Why the strategic benefits of outsourcing formulation development matter

The formulation development outsourcing market continues to grow at pace as pharmaceutical companies experience first-hand the strategic advantages that a solid partnership has in terms of driving resource optimisation, accelerating time to market and enhancing competitive advantage
Manufacturing

Asynt and Almac team up on bespoke reactor vessels

The two companies have teamed up design and supply a range of bespoke reactor vessels, highlighting the benefits of utilising Asynt's lab vessels to streamline Almac Sciences' scale-up process
Subscribe now